文献速递淋巴瘤

MALT淋巴瘤预后指数

A MALT lymphoma prognostic index.
PubMed 文献 · Blood · 2017-07-18

研究基于IELSG-19试验401例患者,用Cox回归构建MALT淋巴瘤预后指数(MALT-IPI),并在633例验证集中确认。年龄≥70岁、Ann Arbor III/IV期和乳酸脱氢酶升高为独立预后因素,据此分为低、中、高危三组,5年无事件生存率分别为70%、56%和29%。

要点

  • MALT-IPI由年龄≥70岁、III/IV期和乳酸脱氢酶升高三项构成,低、中、高危分别对应0、1、≥2项因素。
  • 低、中、高危组5年无事件生存率分别为70%、56%和29%。
  • MALT-IPI在胃与非胃淋巴瘤及各治疗组中均保留预后价值,并在验证集中得到确认。

核心结论

  • MALT-IPI是简单、可及且有效的工具,可识别预后不良的MALT淋巴瘤患者,可能有助于为个体患者确定合适的治疗方式。

研究设计与样本

  • 用Cox回归(逐步选择法)基于国际随机IELSG-19试验(NCT 00210353)入组的401例患者数据构建预后指数。
  • 验证集由3个独立MALT淋巴瘤患者队列合并而成,共633例患者。

主要发现

  • 对无事件生存(EFS,IELSG-19试验的主要终点)保持最强预后意义的三项特征为:年龄≥70岁(HR 1.72;95%CI 1.26-2.33)、Ann Arbor III或IV期(HR 1.79;95%CI 1.35-2.38)、乳酸脱氢酶水平升高(HR 1.87;95%CI 1.27-2.77)。
  • 由上述3项参数构建的预后指数(MALT-IPI)识别出低、中、高危3组,分别对应存在0、1或≥2项因素。
  • 低、中、高危组的5年EFS率分别为70%、56%和29%。
  • MALT-IPI在进展-free生存、总生存和病因特异性生存方面也显著区分不同患者。
  • 预后价值在胃与非胃淋巴瘤中、各治疗组(苯丁酸氮芥、利妥昔单抗、利妥昔单抗联合苯丁酸氮芥)中均保留,并在验证集中得到确认。

关键数值与推荐

  • 年龄≥70岁:HR 1.72(95%CI 1.26-2.33)。
  • Ann Arbor III或IV期:HR 1.79(95%CI 1.35-2.38)。
  • 乳酸脱氢酶水平升高:HR 1.87(95%CI 1.27-2.77)。
  • 低危(0项因素)5年EFS率70%,中危(1项因素)56%,高危(≥2项因素)29%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There are no widely accepted prognostic indices for extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT). This study aimed to develop and validate a specific prognostic tool to personalize and optimize treatment of patients with MALT lymphoma. A prognostic index was built by Cox regression (stepwise selection) using data from 401 patients enrolled in the international randomized International Extranodal Lymphoma Study Group 19 (IELSG-19) trial (NCT 00210353). A validation set, including 633 patients, was obtained by merging 3 independent cohorts of MALT lymphoma patients. The 3 individual features maintaining the greatest prognostic significance for event-free survival (EFS, the main endpoint of the IELSG-19 trial) were age ≥70 years (hazard ratio [HR], 1.72; 95% confidence interval [CI], 1.26-2.33), Ann Arbor stage III or IV (HR, 1.79; 95% CI ,1.35-2.38), and an elevated lactate dehydrogenase level (HR, 1.87; 95% CI, 1.27-2.77). The prognostic index (MALT-IPI) constructed using these 3 parameters identified 3 groups: low, intermediate, and high risk (corresponding to the presence of 0, 1, or ≥2 of these factors, respectively). The 5-year EFS rates in the low-, intermediate-, and high-risk groups were 70%, 56%, and 29%, respectively. The MALT-lymphoma International Prognostic Index (MALT-IPI) also significantly discriminated between patients with different progression-free, overall, and cause-specific survival. The prognostic utility was retained in gastric and nongastric lymphomas, in each treatment arm (chlorambucil, rituximab, and rituximab plus chlorambucil), and was confirmed in the validation set. The new index, MALT-IPI, is a simple, accessible, and effective tool to identify MALT lymphoma patients at risk of poor outcomes. It may help define appropriate treatment approaches for individual patients.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Thieblemont C, Cascione L, Conconi A, et al. A MALT lymphoma prognostic index. Blood. 2017. PMID: 28720586. doi:10.1182/blood-2017-03-771915

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。